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Abstract
Background: Psychosis is rare in untreated patients with Parkinson's disease (PD) but the
prevalence rises to 40% during dopaminergic treatment. So far, no systematic comparison of the
psychogenic potential of different dopaminergic drugs had been performed.
Methods: Eighty PD patients with psychotic episodes were compared to an age-matched control
group of PD patients without psychotic episodes (n = 120) in a cross-sectional retrospective study.
Results: We found a positive correlation between psychotic episodes and dementia, number of
concomitant medication, and pergolide intake. Odds ratio calculation confirmed the association
with dementia. With respect to dopaminergic treatment, pergolide showed the highest odds ratio,
levodopa the lowest. An adjusted logistic regression model confirmed the strong association with
psychotic episodes and pergolide and no association with levodopa (adjusted odds ratio 2.01 and
0.11, respectively).
Conclusion: The analysis indicates that dementia and concomitant medication are factors in PD
associated with psychotic symptoms. Furthermore, different dopaminergic drugs showed markedly
different associations with psychotic symptoms
Background
Idiopathic Parkinson's disease (PD) is the second most
common neurodegenerative disorder. Although it is
mainly classified as a movement disorder, non-motor
symptoms such as psychiatric complications are a regular
phenomenon during disease progression [1,2]. Although
less common than depression [3], psychosis is well-
known as a highly relevant psychiatric symptom in PD.
Psychotic symptoms occur only in a minority (less than
10%) of untreated PD patients but are known to be asso-
ciated with dopaminergic treatment [4-6]. Hallucinations
or illusions are observed in up to 40% of PD patients
treated with dopaminergic drugs [7-12]. Psychosis in PD
patients is associated with excessive disability, worse qual-
ity of life, poor outcome, caregiver distress [1,2], cognitive
impairment, and sleep disturbances [10]. There are multi-
ple factors which are considered to elevate the risk for the
development of psychotic syndromes, i.e. higher age,
duration of disease, microvascular changes, brain atro-
phy, polypharmacotherapy, cognitive impairment,
depression, and sleep disturbances [7,8,10,12-15]. In
addition, the application of anticholinergic drugs, other
reasons for a cholinergic deficit or temporal Lewy bodies
can contribute to the development of psychosis in PD
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ders distinct from PD, such as Dementia with Lewy bodies
(DLB) or Progressive Supranunclear Palsy (PSP), psycho-
sis is also a common phenomenon [16-18], but this has
not been addressed in this study.
Dopaminergic treatment seems to be a particular risk fac-
tor for psychoses in PD. Several reports have described an
induction of psychosis by most of the common dopamine
agonists (DA) [19-26]. Papapetropoulos et al. concluded
that virtually all anti-Parkinsonian drugs are able to
induce psychotic symptoms [27]. The question whether
certain dopaminergic drugs do have a higher potential to
induce psychosis than others is discussed in a controver-
sial manner. In a study of Aarsland et al., the authors
found no correlation at all between anti-Parkinsonian
drugs (levodopa and DA) and hallucinations [12]. In con-
trast, a prospective comparison of patients treated with
either levodopa or ropinirole demonstrated a higher inci-
dence of hallucinations in the ropinirole group (17% vs.
6%) [24,28]. In the present retrospective study, possible
correlations between dopaminergic treatment with differ-




Monocentric, retrospective, cross sectional case control
study. The study was approved by the ethics committee of
the University of Ulm, Germany (reference number: EK
18/09).
Patient sample
The archives of the outpatient clinic for Movement Disor-
ders, University of Ulm, Germany were screened for
patients with PD who simultaneously had a history of
psychotic symptoms (hallucinations, illusions, delusions,
paranoia) in the observation period between 2000 and
2005 as documented in the patient charts. In total, 1,200
patient charts were reviewed. The chart review was per-
formed by trained neurologists with long standing experi-
ence in movement disorders. Only patients with a PD
according to the "UK brain bank criteria" were included,
and only patients with dopaminergic medication in
approved dosages were included. No off-label-use was
allowed. Patients with anticholinergic drugs were not con-
sidered for the analysis. Cholinesterase inhibitors were
not yet approved for the treatment of dementia in PD in
the observation period and were therefore not used.
Amantadine, which is known to be able to induce psy-
chotic symptoms, was even less frequent in the group with
psychosis than in the control group (psychosis group,
1.25% vs. controls, 12.50%). In addition, patients with
other tentative aetiology that may be responsible for psy-
chosis such as infections were also excluded, as well as
patients with incomplete or vague data. For n = 80
patients, we found a complete dataset. This sample was
compared to an age-matched control sample (n = 120) of
PD patients without any recorded psychotic symptoms in
the same observation period.
Investigated Parameters
In all patients who were included in the analysis, psycho-
sis had been diagnosed during the treatment in the outpa-
tient clinic. The occurrence of psychotic symptoms was
collected according to the questions of the "Neuropsychi-
atric Inventory" [29]. The occurrence of psychotic symp-
toms was correlated with the dopaminergic drug
treatment at the time of diagnosis of psychotic symptoms,
patient age, all concomitant medication and all concomi-
tant diseases as documented in the patient chart, white
matter lesions and cortical brain atrophy as described in
the MRI results in the patient chart, and dementia. The
clinical-radiological evaluation as recorded in the patient
chart was used, no re-evaluation of the MRI scans was per-
formed. Dementia was diagnosed by trained neuropsy-
chologists with a long standing experience in dementia in
PD on the basis of a neuropsychological screening accord-
ing to the "Screening for Cognitive Impairment" proposed
by Beinhoff et al. [30] after an initial Mini Mental Status
Examination performed by the neurologist. This screening
method included the Letter Sorting Test (LST) for the
assessment of working memory and concentration, the
subscale orientation of the ADAScog for assessment of ori-
entation, the Memory Impairment Screen (MIS) for
assessment of memory, the Boston Naming Test (BNT) for
assessment of naming deficits, a test of verbal fluency
(VF), and the clock drawing test (CDT). Values of 5 or less
in the MIS and 20 or less in VF, respectively, were pro-
posed by the authors as thresholds to indicate for mild
cognitive impairment and dementia. We limited the anal-
ysis to the most frequently used dopaminergic drugs in
this sample (pergolide, cabergoline, ropinirole, pramipex-
ole, and levodopa), since the number of patients treated
with other DAs were too low for statistical analysis. All
investigated dopaminergic drugs were used with maximal
dosages as follows, levodopa 1000 mg/d, pergolide, 6 mg/
d, cabergoline 6 mg/d, ropinirole 24 mg/d, pramipexole
2.8 mg/d. The investigated dopaminergic drugs were com-
pared with regard to their action at D-, 5-HT- and α2-
receptors.
Statistics
SAS software (SAS institute, Cary, NC) was used in a first
step for correlation analysis (Spearman-Pearson) and the
calculation of odds ratios. In a second step, the data were
analyzed using a logistic regression model adjusted for
sex, dementia, concomitant medication, concomitant dis-
orders and dosages (levodopa equivalence doses). For the
calculation of the levodopa equivalence doses we used thePage 2 of 6
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pramipexole × 67; ropinirole × 16,67; pergolide × 100;
bromocriptine × 10, cabergoline × 100 which orientate at
the official guidelines for diagnostic and therapy of Par-
kinsonian syndromes of the German neurological society
(DGN), 4th revised version 2008. MRI-based parameters
(white matter lesions and cortical brain atrophy) could
not be included in this model since only a limited number
of patients (n = 84 in the group with psychotic symptoms,
n = 50 in the control group) had a high quality MRI scan.
The disease duration, which may also have an influence
on the probability to develop psychotic symptoms, was
not included in the analysis, since not all patients treated
in our outpatient clinic were also initially diagnosed in
our clinic. Therefore, only records with unconfirmed his-
tory data were available which we did not use. P values <
0.05 were considered statistically significant.
Results
Demographic data
Between the group of PD patients with a positive history
of psychotic symptoms (n = 80, mean age 72 years, 54%
male, 46% female) and the control group (n = 120, mean
age 72 years, 69% male, 31% female), there were no sig-
nificant differences in age, gender and number of con-
comitant diseases (Table 1). In the group with psychotic
symptoms 21.25% took cabergoline, 10.00% took prami-
pexole, 21.25% took pergolide and 23.75% took rop-
inirole. In the control group, 25.83% took cabergoline,
17.50% took pramipexole, 10.83% took pergolide and
20.83% took ropinirole.
Correlation analysis
The highest positive correlation was found for the occur-
rence of psychotic episodes and dementia (p = 0.007), fol-
lowed by the number of concomitant diseases (p =
0.020), the number of concomitant medication (p =
0.039), and pergolide intake (p = 0.044). There was a
trend for the correlation of psychotic symptoms and cor-
tical brain atrophy (p = 0.072) as well as for the presence
of white matter lesions (p = 0.33). There was no signifi-
cant correlation between the occurrence of psychotic
symptoms and the use of other dopaminergic medication
(ropinirole, p = 0.731; pramipexole, p = 0.103; cabergo-
line, p = 0.171). In contrast, there was a significant corre-
lation between fewer psychotic episodes and levodopa
treatment (p < 0.001).
Odds ratio
Odds ratio calculation showed the highest risk for psy-
chotic episodes in patients with cortical brain atrophy and
dementia. With respect to dopaminergic treatment, per-
golide showed by far the highest odds ratio, whereas lev-
odopa treatment showed the lowest one; for a synopsis of
odds ratios and confidence intervals, cf. Table 2.
Logistic regression model
The logistic regression model (Table 2/Figure 1) con-
firmed these results. Pergolide had an adjusted odds ratio
of 2.01 showing a markedly increased risk, and levodopa
had an adjusted odds ratio of 0.11 showing a decreased
risk for the occurrence of psychotic symptoms. For all
other dopaminergic drugs investigated, statistically relia-
ble statements were not possible due to adjusted odds
near 1 and overlapping confidence intervals (Figure 1).
Discussion
The occurrence of psychotic episodes in PD patients was
shown to correlate with the presence of dementia and the
numbers of concomitant diseases and of concomitant
drugs, whereas MRI-based factors of cortical atrophy and
white matter lesions could not be finally assessed due to
limited data. With respect to dopaminergic treatment, per-
golide was associated with a significantly increased risk
for the development of psychotic symptoms, whereas lev-
odopa was found to bear the lowest risk of all investigated
dopaminergic drugs. In the literature, there is a large vari-
ability in the reported incidence of PD-associated psycho-
sis among different authors, particularly depending on the
method used [7-12,31]. Prospective studies mostly show
higher incidence rates than retrospective investigations. In
one retrospective study with outpatients, the incidence
was as low as 3% [31]. Some investigators found no clear
association between psychosis in PD and dopaminergic
Table 1: Overview over epidemiological date of the sample of 
psychotic and non-psychotic patients
Parameters Psychosis No Psychosis
N 80 120
Age 72.2 (± 8.6) 71.9 (± 7.1)
sex ratio f/m 0.82 0.75
concomitant diseases 3.1 (± 2.1) 3.7 (± 2.3)
Mean values of parameters with standard deviation in brackets. N = 
number of patients, f = female, m = male
Table 2: Overview of odds ratio calculation and logistic 
regression model data.
Odds ratio Adjusted Odds
cortical atrophy1 2.47 (1.83–18.62)1 NA
dementia 1.98 (1.03–5.51) NA
white matter lesions1 1.19 (0.54–5.51)1 NA
pergolide 2.22 (1.01–4.87) 2.01 (1.22–5.45)
ropinirole 1.18 (0.60–2.32) 1.05 (0.55–2.11)
pramipexole 0.52 (0.22–1.24) 0.94 (0.33–1.66)
cabergoline 0,32 (0.16–0.63) 0.65 (0.39–1.09)
levodopa 0.14 (0.07–0.26) 0.11 (0.06–0.19)
1Calculated for n = 89. Confidence interval in brackets. Pergolide and 
levodopa data in bold for accentuation. NA = not applicablePage 3 of 6
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psychosis in PD and polypharmacotherapy [33]. In the
present study, a positive correlation between the number
of overall used drugs per patient and the risk to develop
psychotic symptoms was observed.
Aarsland et al. described a correlation between higher age
and the incidence of psychosis in PD patients [12]. The
peak age of onset of PD is 55 to 66 years [34], while the
median age of our PD patient sample with psychotic epi-
sodes was 72 ± 9 years. Whether this indicates a correla-
tion of psychotic symptoms with age itself or with the
duration of the disease, as described previously by Fene-
lon et al. [9] cannot be distinguished as no reliable data
concerning disease duration are available in all patients
(see "Statistics")
Based upon the consideration that a main risk factor for
the development of psychosis in PD is the application of
dopaminergic medication itself [5,9,12], it was our aim to
investigate the potential of different dopaminergic drugs
to induce psychotic episodes. In randomized double-
blind trials investigating different DAs the incidence of
hallucinations was 8.1% for priribedil, 2.8% for bromoc-
riptine, 4% for rotigotine, 5% for ropinirole, 7%–9.3% for
pramipexole, 4.8% cabergoline, 3.4 for pergolide, 0% –
4.4% for levodopa [35-40]. As in these studies often early
PD stages (Hoehn and Yahr stage 1–2.5) without severe
concomitant diseases are enrolled, these values represent
not necessarily the situation in "real life".
This study was performed in the assumption that each
included PD patient was treated with an individually opti-
mized DA dose with respect to the efficacy on motor
symptoms. By far the highest association for the induction
of psychotic episodes was observed for pergolide. Since
this association was much lower for cabergoline, i.e. also
an ergoline DA, the high risk for psychosis in pergolide
treatment cannot solely be explained as a group effect.
All investigated DAs behave as highly effective D2 agonists
[41] and, to a lower extent, D3 agonists [42]. Therefore
Adjusted odds ratios for levodopa, cabergoline, pramipexole ropinirole and pergolideFig r  1
Adjusted odds ratios for levodopa, cabergoline, pramipexole ropinirole and pergolide. Results of the logistical 
regression model adjusted for sex, dementia, concomitant medication and concomitant disorders. Box marks indicate odds 
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receptors may play a role. Remarkably many antipsychotic
agents show marked antagonism at D4 receptors [43]. Lev-
odopa – the drug with the lowest risk for psychosis in the
present investigation – has only low affinity to D4 recep-
tors [43]. Also cabergoline and pramipexole, the two DAs
which showed the lowest adjusted odds ratios in this
study (0.58 and 0.64, respectively) have a lower agonistic
efficacy (Emax 49 and 42) at the D4 receptor [41] than per-
golide (Emax 56, adjusted odds ratio 2.8). Another notice-
able point is the investigated DA's α2 receptor affinity:
Only pergolide shows a significant agonistic effect at α2
receptors. In contrast, cabergoline behaves as a strong
antagonist at α2 receptors, whereas ropinirole and prami-
pexole are mostly inactive at α receptors [41]. Further,
both cabergoline and pergolide are 5-HT2A-C receptor ago-
nists [44] and especially 5-HT2A receptors are suspect to be
related to the development of hallucinations [45,46]. In
the comparison of all hereby investigated DAs, pergolide
shows the strongest agonistic effect at the 5-HT2A receptor
[44]. This profile of pergolide as a strong agonist at 5-HT2
and α2 receptors resembles the pharmacological profile of
amphetamine derivates [45]. Therefore we conclude that
the unique pharmacological profile of pergolide (strong
D2 and D4 receptor agonism in combination with strong
5-HT2a and α2 receptor agonism) might contribute to the
high association of pergolide with the induction of psy-
chosis.
Our analysis confirmed that levodopa shows the lowest
risk of all investigated drugs for the development of psy-
chotic episodes in PD. In accordance with this result, Hol-
royd et al. found no association between dose and
duration of levodopa treatment and the development of
hallucinations at all [32]. Thus, the common clinical prac-
tice to use levodopa in psychotic PD patients rather than
DAs is plausible.
Because of the design as a monocentric, retrospective,
cross sectional study, there are certainly intrinsic limita-
tions to the results. We are aware that the influence of dif-
ferent dopaminergic drugs is difficult to interpret. The
dosages are hard to compare due to different pharmacok-
inetic and pharmacodynamic characteristics of the differ-
ent DA. There is also no generally accepted "levodopa
equivalent dose". The levodopa equivalent doses of differ-
ent dopaminergic drugs vary substantially since they
result in general from the consensus of an expert commit-
tee and refer only to the effect on the motor symptoms.
Nevertheless we included the calculated levodopa equiva-
lence doses as a confounder to the logistic regression
model to exclude significantly higher dosage in the psy-
chosis group.
Conclusion
Being well aware of the intrinsic methodological limita-
tions which this retrospective, cross sectional study has,
we could nevertheless demonstrate by systematic data
analysis in a well defined patient sample that PD-associ-
ated psychosis correlates both with epidemiological fac-
tors and with the choice of different dopaminergic drugs.
These factors might be included in differential therapeutic
considerations in order to minimize the risk of psychosis.
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